← All trials
NCT02483858
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Jul 1, 2018
- Completion date
- Nov 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- PIQUR Therapeutics AGLead sponsor
- Mayo ClinicOverall official - principal investigator
- Case Western Reserve UniversityOverall official - principal investigator
- University of LondonOverall official - principal investigator
- University of BaselOverall official - principal investigator
- Mayo ClinicCollaborator
- Case Western Reserve UniversityCollaborator
- University of BarcelonaCollaborator
- University of Texas at HoustonCollaborator
- University of LondonCollaborator
- University of OxfordOverall official - principal investigator
- University of OxfordCollaborator
- State University of New York, BuffaloStudy director
- State University of New York, BuffaloCollaborator
- University of Texas at HoustonOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.